Literatur
Alberici F, Smith RM, Jones RB et al (2015) Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford) 54:1153–1160
Chan V, Charles BG, Tett SE (2005) Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis. Br J Clin Pharmacol 60:257–264
Chanouzas D, Mcgregor JAG, Nightingale P et al (2019) Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study. BMC Nephrol 20:58
Charles P, Dechartres A, Terrier B et al (2020) Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis. Rheumatology (Oxford). https://doi.org/10.1093/rheumatology/kez063.029
Charles P, Perrodeau E, Bonnotte B et al (2019) Comparions between long-term and conventional rituximab-maintenance treatments: results of a plecebo-controlled randomized trial. Arthritis & rheumatology (Hoboken, N.J.) 71 (Suppl 10). https://acrabstracts.org/comparison-between-long-termn-and-conventional-rituximab-maintenance-treatments-results-of-a-placebo-controlled-randomized-trial/. Zugegriffen: 30. März 2020
Charles P, Terrier B, Perrodeau E et al (2018) Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis 77:1143–1149
Csernok E, Hellmich B (2020) Usefulness of vasculitis biomarkers in the era of the personalized medicine. Autoimmun Rev 19(5):102514
Csernok E, Mahrhold J, Hellmich B (2018) Anti-neutrophil cytoplasm antibodies (ANCA): recent methodological advances-lead to new consensus recommendations for ANCA detection. J Immunol Methods 456:1–6
De Groot K, Aries PM, Haubitz M et al (2020) Anti-B-Zell Therapie zur Remissionserhaltung bei Granulomatose mit Polyangiitis und mikroskopischer Polyangiitis. Dtsch Med Wochenschr 145:40–46
De Joode AAE, Sanders JSF, Puechal X et al (2017) Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data. Rheumatology. https://doi.org/10.1093/rheumatology/kex281
Deshayes S, Martin Silva N, Khoy K et al (2019) Clinical impact of subgrouping ANCA-associated vasculitis according to antibody specificity beyond the clinicopathological classification. Rheumatology (Oxford) 58:1731–1739
Faurschou M, Westman K, Rasmussen N et al (2012) Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64:3472–3477. https://doi.org/10.1002/art.34547
Flossmann O, Berden A, De Groot K et al (2011) Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70:488–494
Guillevin L, Pagnoux C, Karras A et al (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371:1771–1780. https://doi.org/10.1056/NEJMoa1404231
Harper L, Morgan MD, Walsh M et al (2012) Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 71:955–960. https://doi.org/10.1136/annrheumdis-2011-200477
Hiemstra TF, Walsh M, Mahr A et al (2010) Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 304:2381–2388
Jayne D, Blockmans D, Luqmani R et al (2019) Efficacy and safety of belimumab and azathioprine for maintenance of remission in antineutrophil cytoplasmic antibody-associated Vasculitis: a randomized controlled study. Arthritis Rheumatol 71:952–963
Jones RB, Hiemstra TF, Ballarin J et al (2019) Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Ann Rheum Dis 78:399–405
Karras A, Pagnoux C, Haubitz M et al (2017) Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis 76:1662–1668
Kronbichler A, Kerschbaum J, Gopaluni S et al (2018) Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 77:1440–1447
Lionaki S, Blyth ER, Hogan SL et al (2012) Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 64:3452–3462
Lionaki S, Hogan SL, Jennette CE et al (2009) The clinical course of ANCA small-vessel vasculitis on chronic dialysis. Kidney Int 76:644–651
Mcclure ME, Wason J, Gopaluni S et al (2019) Evaluation of PR3-ANCA status after rituximab for ANCA-associated vasculitis. J Clin Rheumatol 25:217–223
Mcgeoch L, Twilt M, Famorca L et al (2016) CanVasc recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitides. J Rheumatol 43:97–120
Metzler C, Miehle N, Manger K et al (2007) Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener’s granulomatosis. Rheumatology (Oxford) 46:1087–1091
Montante A, Le Bras A, Pagnoux C et al (2019) Cost-effectiveness of rituximab versus azathioprine for maintenance treatment in antineutrophil cytoplasmic antibody-associated vasculitis. Clin Exp Rheumatol 37(Suppl 117):137–143
Morgan MD, Szeto M, Walsh M et al (2017) Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse. Arthritis Res Ther 19:129
Ntatsaki E, Carruthers D, Chakravarty K et al (2014) BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford) 53:2306–2309
Pagnoux C, Mahr A, Hamidou MA et al (2008) Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 359:2790–2803
Pierrot-Deseilligny Despujol C, Pouchot J, Pagnoux C et al (2010) Predictors at diagnosis of a first Wegener’s granulomatosis relapse after obtaining complete remission. Rheumatology (Oxford) 49:2181–2190
Roberts DM, Jones RB, Smith RM et al (2014) Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun 31:173–175
Salmela A, Rasmussen N, Tervaert JWC et al (2017) Chronic nasal Staphylococcus aureus carriage identifies a subset of newly diagnosed granulomatosis with polyangiitis patients with high relapse rate. Rheumatology (Oxford) 56:965–972
Salmela A, Törnroth T, Poussa T et al (2018) Prognostic factors for survival and relapse in ANCA-associated vasculitis with renal involvement: a clinical long-term follow-up study. Int J Nephrol 2018:1–11. https://doi.org/10.1155/2018/6369814
Schirmer JH, Aries PM, De Groot K et al (2017) S 1 Leitlinie zur Diagnose und Therapie der ANCA-assoziierten Vaskulitiden. Z Rheumatol 76:77–104
Smith R, Jayne D, Merkel P (2019) A randomized, controlled trial of rituximab versus azathioprine after induction of remission with rituximab for patients with ANCA-associated vasculitis and relapsing disease [abstract]. Arthritis & rheumatology 71. https://acrabstracts.org/abstract/a-randomized-controlled-trial-of-rituximab-versus-azathioprine-after-induction-of-remission-with-rituximab-for-patients-with-anca-associated-vasculitis-and-relapsing-disease/. Zugegriffen: 6. Jan. 2020
Solans-Laqué R, Fraile G, Rodriguez-Carballeira M et al (2017) Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides: Impact of the vasculitis type, ANCA specificity, and treatment on mortality and morbidity. Medicine (Baltimore) 96:e6083
Stegeman CA, Tervaert JW, De Jong PE et al (1996) Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 335:16–20
Terrier B, Pagnoux C, Perrodeau E et al (2018) Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann Rheum Dis 77:1150–1156
Thery-Casari C, Euvrard R, Mainbourg S et al (2020) Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: A meta-analysis. Autoimmun Rev 19(5):102505
Vandenbussche C, Bitton L, Bataille P et al (2019) Prognostic value of microscopic hematuria after induction of remission in antineutrophil cytoplasmic antibodies-associated vasculitis. Am J Nephrol 49:479–486
Venhoff N, Effelsberg NM, Salzer U et al (2012) Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. Plos One 7:e37626. https://doi.org/10.1371/journal.pone.0037626
Walsh M, Flossmann O, Berden A et al (2012) Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64:542–548
Walsh M, Merkel PA, Mahr A et al (2010) Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res 62:1166–1173
Yates M, Watts RA, Bajema IM et al (2016) EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75:1583–1594
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
B. Hellmich war als Koautor an der Erstellung der EULAR-Recommendations 2009 und 2016 und der DGRh-Leitlinie zum Management der AAV beteiligt und hat folgende Zuwendungen von der Industrie erhalten: Vortragshonorare: AbbVie, BMS, Celgen, Novartis, Orgentec, Pfizer, Roche. Honorare für Beratungsleistungen: BMS, InflaRx, GSK, Roche.
Für diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Additional information
Redaktion
J. Holle, Neumünster
F. Moosig, Neumünster
Rights and permissions
About this article
Cite this article
Hellmich, B. ANCA-assoziierte Vaskulitiden nach Erreichen einer Remission. Z Rheumatol 79, 696–701 (2020). https://doi.org/10.1007/s00393-020-00828-w
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00393-020-00828-w